Bevacizumab therapy for POEMS syndrome

被引：84

作者：

Badros, A ^{[1
]}

Porter, N ^{[1
]}

Zimrin, A ^{[1
]}

机构：

[1] Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA

来源：

BLOOD | 2005年 / 106卷 / 03期

关键词：

D O I：

10.1182/blood-2005-03-0910

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1135 / 1135

页数：1

共 7 条

[1] POEMS syndrome: definitions and long-term outcome [J].

Dispenzieri, A ;

Kyle, RA ;

Lacy, MQ ;

Rajkumar, SV ;

Therneau, TM ;

Larson, DR ;

Greipp, PR ;

Witzig, TE ;

Basu, R ;

Suarez, GA ;

Fonseca, R ;

Lust, JA ;

Gertz, MA .

BLOOD, 2003, 101 (07) :2496-2506

[2] POEMS syndrome and VEGF [J].

Hayashi, T .

INTERNAL MEDICINE, 2004, 43 (11) :1014-1014

[3] POEMS syndrome demonstrating VEGF decrease by ticlopidine [J].

Matsui, H ;

Udaka, F ;

Kubori, T ;

Oda, M ;

Nishinaka, K ;

Kameyama, M .

INTERNAL MEDICINE, 2004, 43 (11) :1082-1083

[4] The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications [J].

Podar, K ;

Anderson, KC .

BLOOD, 2005, 105 (04) :1383-1395

[5]

Watanabe O, 1998, MUSCLE NERVE, V21, P1390, DOI 10.1002/(SICI)1097-4598(199811)21:11<1390::AID-MUS5>3.3.CO

[6]

2-S

[7] Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome [J].

Watanabe, O ;

Arimura, K ;

Kitajima, I ;

Osame, M ;

Maruyama, I .

LANCET, 1996, 347 (9002) :702-702

← 1 →